Page last updated: 2024-12-08

jib-04

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

JIB-04: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID392778
MeSH IDM0589992

Synonyms (5)

Synonym
NCI60_033523
NCICHAL_000041
jib-04
nsc 693627
AKOS026750240

Research Excerpts

Compound-Compound Interactions

The study also tested siEphA2-loaded nanoparticles in combination with a histone lysine demethylase inhibitor, JIB-04. Preliminary results were presented for the first time.

ExcerptReferenceRelevance
" After verifying the efficacy of siEphA2-loaded nanoparticles, we further evaluated a potential combination with a histone lysine demethylase inhibitor, JIB-04."( Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Baird, AM; Bozkurt, E; Debelec Butuner, B; Finn, SP; Gray, SG; Kantarci, AG; Kotmakci, M; Oner, E, 2021
)
0.82
" Moreover, preliminary results of the effects of JIB-04, alone and in combination with siEphA2, on prostate cancer cells and prostate cancer tumor spheroids were presented for the first time."( Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Baird, AM; Bozkurt, E; Debelec Butuner, B; Finn, SP; Gray, SG; Kantarci, AG; Kotmakci, M; Oner, E, 2021
)
0.88

Bioavailability

ExcerptReferenceRelevance
" To enhance the bioavailability of siRNAs in tumors, novel, safe, and effective carriers are needed."( Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Baird, AM; Bozkurt, E; Debelec Butuner, B; Finn, SP; Gray, SG; Kantarci, AG; Kotmakci, M; Oner, E, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (52.38)24.3611
2020's10 (47.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.70 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index30.30 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (27.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]